

# Michael Scharl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5616046/publications.pdf>

Version: 2024-02-01

172  
papers

13,344  
citations

87888

38  
h-index

23533

111  
g-index

175  
all docs

175  
docs citations

175  
times ranked

26225  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoimmune susceptibility gene <i>PTPN2</i> is required for clearance of adherent-invasive <i>Escherichia coli</i> by integrating bacterial uptake and lysosomal defence. <i>Gut</i> , 2022, 71, 89-99.	12.1	9
2	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 560-571.	1.9	20
3	Ingested nano- and micro-sized polystyrene particles surpass the intestinal barrier and accumulate in the body. <i>NanoImpact</i> , 2022, 25, 100374.	4.5	20
4	pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1419.	4.1	9
5	From Patient Material to New Discoveries: a Methodological Review and Guide for Intestinal Stem Cell Researchers. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1309-1321.	3.8	2
6	Inhibition of integrin $\alpha 5 \beta 1$ sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
7	Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol. <i>BMJ Open</i> , 2022, 12, e061421.	1.9	7
8	Loss of PTPN2 Activity Alters Iron Handling Protein Expression in IBD Patients and Causes Iron Deficiency in Mice. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
9	Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2565-2565.	1.6	0
10	Novel Strategies to Prevent Total Parenteral Nutrition-Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e1901270.	3.3	14
11	Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. <i>Digestion</i> , 2021, 102, 453-461.	2.3	1
12	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF- $\alpha$ Overexpression in Crohn Disease-Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 538-549.	1.9	11
13	Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000412.	3.3	8
14	The JAK Inhibitor Tofacitinib Rescues Intestinal Barrier Defects Caused by Disrupted Epithelial-macrophage Interactions. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 471-484.	1.3	30
15	Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 287-298.	1.3	4
16	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110020.	3.2	11
17	Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene <i>Ptpn2</i> in Myeloid Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 772.	4.1	2
18	Energy Drink Administration Ameliorates Intestinal Epithelial Barrier Defects and Reduces Acute DSS Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1139-1152.	1.9	4

#	ARTICLE	IF	CITATIONS
19	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 140-153.	1.9	13
20	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	16
21	Dysbiotic microbiota interactions in Crohn's disease. <i>Gut Microbes</i> , 2021, 13, 1949096.	9.8	38
22	Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1596-1601.	1.3	2
23	Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 187-197.	1.5	1
24	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000514.	3.3	4
25	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	1
26	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD – Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1431-1442.	1.3	39
27	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD – Challenges and Future Directions. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1407-1409.	1.3	7
28	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1986-1998.	1.9	4
29	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 53-67.	3.7	16
30	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6820.	4.1	3
31	Loss of PTPN22 Promotes Intestinal Inflammation by Compromising Granulocyte-mediated Antibacterial Defence. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2118-2130.	1.3	5
32	Spermidine and spermine exert protective effects within the lung. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00837.	2.4	31
33	Tracing colonic embryonic transcriptional profiles and their reactivation upon intestinal damage. <i>Cell Reports</i> , 2021, 36, 109484.	6.4	18
34	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. <i>Cell Host and Microbe</i> , 2021, 29, 1573-1588.e7.	11.0	71
35	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 773-780.	3.8	4
36	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. <i>Microorganisms</i> , 2021, 9, 1752.	3.6	6

#	ARTICLE	IF	CITATIONS
37	Î²6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00395.	2.5	9
38	Efficient treatment of esophageal nutrition bezoars: dissolution outmatches removalâ€”the Zurich approach. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1602-1606.	0.8	2
39	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	33
40	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€”What, Why, and How. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1410-1430.	1.3	28
41	Fatigue in inflammatory bowel disease and its impact on daily activities. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 138-149.	3.7	25
42	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 1-10.	1.9	15
43	MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model. <i>Tissue Barriers</i> , 2021, , 1994350.	3.2	1
44	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. <i>BMC Gastroenterology</i> , 2021, 21, 310.	2.0	0
45	Unravelling the Impact of the Genetic Variant rs1042058 within the TPL2 Risk Gene Locus on Molecular and Clinical Disease Course Patients with Inflammatory Bowel Disease. <i>Cells</i> , 2021, 10, 3589.	4.1	4
46	WNT2b Activates Epithelial-mesenchymal Transition Through FZD4: Relevance in Penetrating Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 230-239.	1.3	29
47	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2019-2029.e11.	4.4	64
48	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2654-2663.	2.3	4
49	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	1.9	17
50	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 1196-1207.	3.8	24
51	The Role of Protein Tyrosine Phosphatases in Inflammasome Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5481.	4.1	11
52	Malignancies in Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 136-145.	2.3	48
53	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. <i>Frontiers in Immunology</i> , 2020, 11, 1856.	4.8	14
54	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095925.	3.2	7

#	ARTICLE	IF	CITATIONS
55	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 170-179.	1.9	3
56	Succinate Activates EMT in Intestinal Epithelial Cells through SUCNR1: A Novel Protagonist in Fistula Development. <i>Cells</i> , 2020, 9, 1104.	4.1	27
57	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1503-1511.	1.3	100
58	PTPN2 Regulates Interactions Between Macrophages and Intestinal Epithelial Cells to Promote Intestinal Barrier Function. <i>Gastroenterology</i> , 2020, 159, 1763-1777.e14.	1.3	62
59	Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1038-1049.	1.9	5
60	Transcriptional and Ultrastructural Analyses Suggest Novel Insights into Epithelial Barrier Impairment in Celiac Disease. <i>Cells</i> , 2020, 9, 516.	4.1	10
61	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628481989521.	3.2	2
62	Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1 $\alpha$ /JNK Pathway in an Intestinal Epithelial Cell Model. <i>Scientific Reports</i> , 2020, 10, 1438.	3.3	32
63	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 685-695.	1.3	1
64	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. <i>EBioMedicine</i> , 2019, 48, 648-655.	6.1	72
65	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986514.	3.2	20
66	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. <i>Mucosal Immunology</i> , 2019, 12, 1336-1347.	6.0	21
67	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). <i>International Journal of Epidemiology</i> , 2019, 48, 385-386f.	1.9	26
68	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. <i>PLoS ONE</i> , 2019, 14, e0210436.	2.5	26
69	Tofacitinib for the Treatment of Pyoderma Gangrenosum. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 991-993.	4.4	48
70	Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor- $\kappa$ B in the Intestinal Epithelium. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 339-355.	4.5	9
71	Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 14-26.	1.9	1
72	Stepwise Development of an in vitro Continuous Fermentation Model for the Murine Caecal Microbiota. <i>Frontiers in Microbiology</i> , 2019, 10, 1166.	3.5	19

#	ARTICLE	IF	CITATIONS
73	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2019, 60, 1270-1283.	4.2	37
74	AMPK mediates inhibition of electrolyte transport and NKCC1 activity by reactive oxygen species. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G171-G181.	3.4	8
75	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. <i>PLoS ONE</i> , 2019, 14, e0211554.	2.5	15
76	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. <i>PLoS ONE</i> , 2019, 14, e0215738.	2.5	5
77	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1292-1301.	1.3	37
78	Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 767-781.	3.8	67
79	The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. <i>BMC Gastroenterology</i> , 2019, 19, 2.	2.0	24
80	Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids. <i>Stem Cell Research</i> , 2019, 35, 101383.	0.7	32
81	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1357-1366.	1.9	5
82	The EB12-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. <i>Mucosal Immunology</i> , 2019, 12, 733-745.	6.0	40
83	Response to Al Sulais et al.. <i>American Journal of Gastroenterology</i> , 2019, 114, 1346-1347.	0.4	1
84	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 161-174.	1.9	6
85	Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 245-258.	1.3	39
86	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 798-806.	1.3	13
87	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 785-797.	1.3	19
88	Î² <sub>6</sub> -integrin serves as a novel serum tumor marker for colorectal carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 678-685.	5.1	42
89	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 116-126.	0.4	39
90	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. <i>Journal of Clinical Investigation</i> , 2019, 129, 2527-2541.	8.2	15

#	ARTICLE	IF	CITATIONS
91	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1875771.	3.2	5
92	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1768-1779.	1.9	32
93	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 811-818.	1.3	88
94	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. <i>Maturitas</i> , 2018, 110, 71-78.	2.4	25
95	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. <i>Cell Reports</i> , 2018, 22, 1835-1848.	6.4	80
96	Validation of the "United Registries for Clinical Assessment and Research" [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 532-537.	1.3	8
97	Expression Patterns of TNF $\alpha$ , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 347-354.	1.3	44
98	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 25-29.	2.2	9
99	PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1465013.	0.7	7
100	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300ml blood ingestion mimicking upper gastrointestinal bleeding. <i>United European Gastroenterology Journal</i> , 2018, 6, 1007-1014.	3.8	14
101	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. <i>PLoS ONE</i> , 2018, 13, e0199664.	2.5	35
102	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1399-1409.	1.3	40
103	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. <i>PLoS ONE</i> , 2018, 13, e0193003.	2.5	7
104	What Distinguishes Mechanisms of Fistula and Stricture Formation. , 2018, , 307-317.		1
105	Mono Sodium Urate Crystal-induced Peritonitis for in vivo Assessment of Inflammasome Activation. <i>Bio-protocol</i> , 2018, 8, e2754.	0.4	4
106	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. <i>Swiss Medical Weekly</i> , 2018, 148, w14599.	1.6	27
107	Genetics and epigenetics of inflammatory bowel disease. <i>Swiss Medical Weekly</i> , 2018, 148, w14671.	1.6	27
108	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. <i>Gut</i> , 2017, 66, 1216-1224.	12.1	223

#	ARTICLE	IF	CITATIONS
109	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. <i>BMJ Open</i> , 2017, 7, e013477.	1.9	7
110	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. <i>Digestive and Liver Disease</i> , 2017, 49, 268-272.	0.9	3
111	A Symptomatic Coffee Bean: Acute Sigmoid Volvulus. <i>Case Reports in Gastroenterology</i> , 2017, 11, 348-351.	0.6	10
112	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 131-138.	1.9	13
113	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. <i>Autophagy</i> , 2017, 13, 1590-1601.	9.1	90
114	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 200-206.	1.8	89
115	Fistulizing Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e106.	2.5	24
116	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 211-218.	1.9	1
117	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. <i>PLoS ONE</i> , 2017, 12, e0185193.	2.5	54
118	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 172-181.	1.9	10
119	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2016, 11, e0154817.	2.5	71
120	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2016, 11, e0155218.	2.5	31
121	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. <i>PLoS ONE</i> , 2016, 11, e0156666.	2.5	104
122	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. <i>PLoS ONE</i> , 2016, 11, e0160215.	2.5	7
123	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. <i>Digestion</i> , 2016, 93, 182-192.	2.3	10
124	Prediction of low bone mineral density in patients with inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2016, 4, 669-676.	3.8	21
125	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. <i>Case Reports in Gastroenterology</i> , 2016, 10, 113-119.	0.6	5
126	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. <i>Digestion</i> , 2016, 93, 249-259.	2.3	11



#	ARTICLE	IF	CITATIONS
127	Anti-MMP-9 Antibody. Inflammatory Bowel Diseases, 2016, 22, 2041-2057.	1.9	64
128	Celiac disease diagnosis still significantly delayed â€“ Doctor's but not patientsâ€™ delay responsive for the increased total delay in women. Digestive and Liver Disease, 2016, 48, 1148-1154.	0.9	30
129	The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis. United European Gastroenterology Journal, 2016, 4, 325-332.	3.8	7
130	The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterology Journal, 2016, 4, 506-514.	3.8	16
131	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
132	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. Journal of Crohn's and Colitis, 2016, 10, 377-386.	1.3	92
133	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Journal of Clinical Investigation, 2016, 126, 1783-1800.	8.2	171
134	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. World Journal of Gastroenterology, 2016, 22, 1034.	3.3	28
135	Patientsâ€™ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? â€“ a patient survey. Nutrition Journal, 2015, 14, 78.	3.4	14
136	Protein Tyrosine Phosphatase Nonreceptor Type 2: An Important Regulator of Interleukinâ€™6 Production in Rheumatoid Arthritis Synovial Fibroblasts. Arthritis and Rheumatology, 2015, 67, 2624-2633.	5.6	32
137	Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1982-1992.	1.9	565
138	Coganâ€™s Syndrome in Patients With Inflammatory Bowel Disease â€“ A Case Series. Journal of Crohn's and Colitis, 2015, 9, 886-890.	1.3	22
139	Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. Clinical and Translational Medicine, 2015, 4, 1.	4.0	108
140	Role of Protein Tyrosine Phosphatases in Regulating the Immune System. Inflammatory Bowel Diseases, 2015, 21, 645-655.	1.9	32
141	Successful treatment of a proximal esophageal rupture with a luminal sponge. Endoscopy, 2015, 47, E293-E294.	1.8	5
142	Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget, 2015, 6, 42183-42196.	1.8	40
143	Bilberry-Derived Anthocyanins Prevent IFN-â€™;#947;-Induced Pro-Inflammatory Signalling and Cytokine Secretion in Human THP-1 Monocytic Cells. Digestion, 2014, 90, 179-189.	2.3	33
144	A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 803-806.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 114-118.	1.6	36
146	Pathophysiology of fistula formation in Crohn's disease. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2014, 5, 205.	1.0	93
147	Su1261 Expression of Interleukins 22 and 33, Matrix Metalloproteinases 9 and 13, Mast Cell Markers and Hypoxia-Inducible Factor 1 $\alpha$ in Crohn's Disease Associated Fistulae. <i>Gastroenterology</i> , 2013, 144, S-441-S-442.	1.3	3
148	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis – An open pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 271-279.	1.3	106
149	Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon- $\gamma$ -Induced Signaling in Human Monocytes. <i>Gastroenterology</i> , 2013, 144, 978-988.e10.	1.3	46
150	A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of Crohn's Disease-Associated Fistulae. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2878-2887.	1.9	27
151	Interleukin-13 and transforming growth factor $\beta$ synergise in the pathogenesis of human intestinal fistulae. <i>Gut</i> , 2013, 62, 63-72.	12.1	108
152	Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis. <i>PLoS ONE</i> , 2013, 8, e73703.	2.5	36
153	The Role for Dickkopf-Homolog-1 in the Pathogenesis of Crohn's Disease-Associated Fistulae. <i>PLoS ONE</i> , 2013, 8, e78882.	2.5	28
154	Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy. <i>PLoS ONE</i> , 2013, 8, e72384.	2.5	38
155	Inflammatory bowel disease pathogenesis. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 301-309.	2.3	72
156	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
157	Inflammatory Bowel Disease: Dysfunction of Autophagy?. <i>Digestive Diseases</i> , 2012, 30, 12-19.	1.9	65
158	Protein Tyrosine Phosphatase Nonreceptor Type 2 Regulates Autophagosome Formation in Human Intestinal Cells. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1287-1302.	1.9	60
159	Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 900-912.	1.9	71
160	The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. <i>Annals of the New York Academy of Sciences</i> , 2012, 1257, 93-102.	3.8	11
161	Protein tyrosine phosphatase N2 regulates TNF $\alpha$ -induced signalling and cytokine secretion in human intestinal epithelial cells. <i>Gut</i> , 2011, 60, 189-197.	12.1	72
162	Association between Cogan's syndrome and inflammatory bowel disease: A case series. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 64-68.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Knock-Out of Î²-Glucosidase 2 Has No Influence on Dextran Sulfate Sodium-Induced Colitis. <i>Digestion</i> , 2011, 84, 156-167.	2.3	9
164	Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1907-1916.	1.9	51
165	Dying in Yoghurt: The Number of Living Bacteria in Probiotic Yoghurt Decreases under Exposure to Room Temperature. <i>Digestion</i> , 2011, 83, 13-17.	2.3	6
166	Protein Tyrosine Phosphatase non-Receptor Type 2 regulates IFN-Î³-induced cytokine signaling in THP-1 monocytes. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2055-2064.	1.9	71
167	Microbial Sensing by the Intestinal Epithelium in the Pathogenesis of Inflammatory Bowel Disease. <i>International Journal of Inflammation</i> , 2010, 2010, 1-12.	1.5	17
168	Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G935-G945.	3.4	24
169	AMP-activated Protein Kinase Mediates the Interferon-Î³-induced Decrease in Intestinal Epithelial Barrier Function. <i>Journal of Biological Chemistry</i> , 2009, 284, 27952-27963.	3.4	93
170	Protection of Epithelial Barrier Function by the Crohn's Disease Associated Gene Protein Tyrosine Phosphatase N2. <i>Gastroenterology</i> , 2009, 137, 2030-2040.e5.	1.3	100
171	Interferon-Î³ induced epithelial barrier dysfunction in T84 human intestinal epithelial cells (IECs) occurs via phosphatidylinositol 3-kinase (PI3K) mediated activation of adenosine monophosphate-activated protein kinase (AMPK). <i>FASEB Journal</i> , 2009, 23, 978.2.	0.5	0
172	Inhibition of Adenosine Monophosphate-activated Protein Kinase (AMPK) ameliorates the effects of Interferon gamma (IFN gamma) on epithelial barrier function in T84 cells. <i>FASEB Journal</i> , 2008, 22, 1189.10.	0.5	0